Mass High Tech - October 23, 2007

VisEn Medical sees $6.9M in second round
Mass High Tech

VisEn Medical Inc., a maker of fluorescence-imaging products, has completed its second round of venture capital financing, according to a regulatory filing.

The Woburn-based firm in recent weeks closed a $6.9 million Series B financing led by Cambridge's Flagship Ventures and Merck Capital Ventures LLC, the venture capital arm of New Jersey-based drug giant Merck & Co. Inc., according to VisEn and U.S. Securities and Exchange Commission records. The company reports that The Bollard Group, of Boston, and other previous investors also participated in the financing.

Company officials said the round would be used to expand the firm's sales and marketing staff, launch new products, and fund research and development of its clinical imaging technology.

Founded in 2000, VisEn has developed and commercialized florescence-in vivo imaging technology first discovered by a researcher at Massachusetts General Hospital and Harvard Medical School. The company has raised a total of $12.5 million in venture funding.